Telefonaktiebolaget Lm Ericsson (Publ)

Inventec Corp.

Micron Technology Incorporated

Shanghai United Imaging Intelligence Co., Ltd.

Other

Eli Lilly and Company

Ecolab USA Inc.

Shanghai United Imaging Healthcare Co., Ltd.

Sichuan University

Basf Se Corporation

Ethicon Endo-Surgery, Inc.

Conopco, Inc.

Abbvie Inc.

Basf Coatings Gmbh

Alcatel Lucent

Shuhui Chen

Jian Li

Wentao Wu

Zhengxia Chen

Iana Siomina

Jianfei Wang

Meibi Dai

Zhixiang Li

Jie Li

Jikui Sun

Zhifei Fu

Miaorong Luo

Haizhong Tan

Guoping Hu

Jian Qin

Liang Chen

Ping Hu

Yang Lyu

Tsai-Kuei Cheng

Sukhwan Soontravanich

Chaofeng Long

Xiaoxin Chen

Zhuowei Liu

William Hunter White

Juan Yu

Fei Hong

Jean Marie Defauw

Jinming Huang

Tingting Yin

Zhiliang Chen

Kishore Kumar Muchherla

Sampath K Ratnam

Vamsi Pavan Rayaprolu

Torbjörn Wigren

Xing Liu

Karl David Schuh

Wei Wang

Peng Li

Jiangang Wu

Åke Busin

Kevin X Chen

Stephan Maria Hubig

Yuquan Wei

Tao Feng

Jing Zhang

Zhen Gong

Shu Liao

Hong Lu

Fei Wang

Chunhui Zhang

Fang Liu

Haiying He

Yuan Chen

Yonghua Li

Ji-Peng Xu

Zheng Wang

Kai Zhou

Zhiwei Zhang

Yang Zhang

Yang Liu

Fei Sun

Jiong Lan

Shan Wan

Wei Gu

Adrian Hobson

Youping Su

Michael M Friedman

Yan Fei Liu

Xuanjia Peng

Martine Barth

Jian Xiong

Shi-Feng Wang

Maria A Argiriadi

Zhiqiang Liu

Bing Deng

Xiao Liu

Jianliang Gu

Qiang Qiu

Xin Qu

Claudia Brunn

Cheng Xie

Eric C Breinlinger

Long Zhang

Dawn M George

Lingyun Gu

Wei Yan

Jingjing Wang

Chunli Shen

Songliang Wu

Di Shu

Didier Thomas

Dominique Bonafoux

Zhenyu Wang

Guibai Liang

Zaifang Ren

The present invention relates to a PD-L1 immunomodulator, and specifically discloses a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.

Fluorovinylbenzamide compound as PD-L1 immunomodulator

Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.

Compound as highly selective ROS1 inhibitor and use thereof

Disclosed is a multi-phase personal care composition comprising an aqueous phase, and an oil phase comprising volatile silicone, fatty acid amide and retinoid, wherein the aqueous phase is visually distinct from and in physical contact with the oil phase.

Personal care composition with visually distinct aqueous and oil phase

The use of a phenylpropionamide compound in the preparation of a drug for treating diseases associated with pain and pruritus. Specifically, the present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

Phenylpropionamide compound and use thereof

The present disclosure discloses a class of macrocyclic derivatives, and specifically discloses a compound shown in formula (VI), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.

Macrocyclic derivative and use thereof

Provided are a class of multi-targeted inhibitors of IRAK4 and BTK, and the use thereof in preparing a drug for treating IRAK4- and BTK-related diseases. The present invention specifically relates to the compounds represented by formula (II), isomers thereof or pharmaceutically acceptable salts thereof.

Oxazole compound as multi-targeted inhibitor of IRAK4 and BTK

Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.

Benzopyrimidine compounds and use thereof

Disclosed are the solid form, crystalline form, crystal form A of a compound of formula (I), and a preparation method therefor, crystal form B and a preparation method therefor. Also disclosed are use of the solid form, crystalline form, crystal form A, and crystal form B in the preparation of drugs for the treatment of diseases related to FGFR.

FGFR inhibitor compound in solid form and preparation method therefor

FGFR and VEGFR dual inhibitors, specifically being a compound represented by formula (I) or a pharmaceutically acceptable salt.

Pyridine derivative as FGFR and VEGFR dual inhibitors

Disclosed are a pyrrolopyrimidine compound and a use thereof in preparing a medicine for diseases related to a BTK protein kinase inhibitor. Specially, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.

Pyrrolopyrimidine compound as BTK inhibitor and use thereof

Provided are a crystal of a compound of formula (I), salt thereof, a crystal of the salt thereof, and a preparation method for the crystal. Also comprised are applications of the compound and the crystal in preparation of drugs for treating IRAK4-related diseases.

IRAK4 inhibitor crystal and preparation method therefor

Suggested are surfactant compositions comprising: One or more alpha-sulfofatty acid disalts (A) of general formula (I), RICH (SO3M1) COOM2 (I), wherein the radical R 1 denotes a linear or branched alkyl or alkenyl radical having 6 to 18 C atoms and the radicals M 1 and M 2-independently of one another-are selected from the group H, Li, Na, K, Ca/2, Mg/2, Ammonium and alkanolamines and one or more polysaccharides (B) selected from the group consisting of dextrin and its derivatives, starch and its derivatives, cellulose and its derivatives, preferably one or more dextrins (B) of the general formula (II), (II) in which n is an integer between 3 and 200.

Aqueous surfactant compositions and soap bars

A fused ring compound as an FGFR and VEGFR dual inhibitor. Particularly, disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Fused ring compound as FGFR and VEGFR dual inhibitor

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

Azaindole derivative and use thereof as FGFR and C-Met inhibitor

Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.

Pyrazolopyridine compound as RET inhibitor and application thereof

Growing community of inventors

Shanghai, China

Shuhui Chen